title: Kinin and opioid receptors in the paratrigeminal nucleus modulate the somatosensory reflex to rat sciatic nerve stimulation.
abstract: The influence of kinin and opioid receptor blockade in the paratrigeminal nucleus (Pa5) on the somatosensory reflex (SSR) to sciatic nerve stimulation (SNS) was assessed in anaesthetized-paralyzed rats. SNS (square 1 ms pulses at 0.6 mA and 20 Hz for 10s) increased mean arterial pressure from 87+/-3 to 106+/-3 mmHg. Pressor responses to SNS were reduced 40-60% by HOE-140 and LF 16-0687 (B2 receptor antagonists; 20 and 100 pmol respectively), CTOP or nor-binaltorphimine (mu and kappa opioid receptor antagonists, respectively; 1 microg) but potentiated by naltrindole (delta opioid receptor antagonist) receptor antagonist microinjections into the contralateral (but not ipsilateral) Pa5. The SSR to sciatic nerve stimulation was not changed by B1 kinin receptor or NK1, NK2 and NK3 tachykinin receptor antagonists administered to the Pa5. Capsaicin pretreatment (40 mg/kg/day, 3 days) abolished the effects of the opioid receptor antagonists, but did not change the effect of kinin B2 receptor blockade on the SSR. Thus, the activity of B2 and opioid receptor-operated mechanisms in the Pa5 contribute to the SSR in the rat, suggesting a role for these endogenous peptides in the cardiovascular responses to SNS.
authors.affiliation: Department of Pharmacology, Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil.
authors.forename: Janice
authors.initials: J
authors.lastname: Koepp
authors.forename: Cristofer André
authors.initials: CA
authors.lastname: Caous
authors.forename: Giles Alexander
authors.initials: GA
authors.lastname: Rae
authors.forename: Antonio Claudir
authors.initials: AC
authors.lastname: Balan
authors.forename: Charles Julian
authors.initials: CJ
authors.lastname: Lindsey
mesh_terms: D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D004558:Electric Stimulation / Q000379:methods; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008954:Models, Biological; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018002:Receptors, Bradykinin / Q000502:physiology*; D011957:Receptors, Opioid / Q000502:physiology*; D012021:Reflex, Abnormal / Q000187:drug effects / Q000502:physiology*; D012584:Sciatic Nerve / Q000187:drug effects / Q000502:physiology*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology; D014278:Trigeminal Nuclei / Q000187:drug effects / Q000502:physiology*
chemical_list: D065168:Bradykinin Receptor Antagonists; C403051:LF 16-0687; D009292:Narcotic Antagonists; D011804:Quinolines; D018002:Receptors, Bradykinin; D011957:Receptors, Opioid; C049352:phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide; C051844:norbinaltorphimine; D013004:Somatostatin; D009271:Naltrexone; C065679:icatibant; D001920:Bradykinin